// App-Quantinova.ai

: Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1

Researchers

Presenter

  • Connie Lee Batlevi

Principal Investigators

  • Gilles Salles

  • Steven I. Park

  • Tycel J. Phillips

  • Jennifer E. Amengual

  • David Andorsky

  • Philip Campbell

  • Pamela McKay

  • John P. Leonard

  • Manu Sondhi

  • Yingxue Chen

  • Pamela L. Slatcher

  • Richard Lin

  • Attila Szanto

  • Sara Abbadi

  • Franck Morschhauser

Medical Centers

  • University of Michigan Medical School, Ann Arbor, MI

  • Lymphoma Service, Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, NEW YORK, NY

  • Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Charlotte, NC

  • Weill Cornell Medicine, New York, NY

  • Memorial Sloan Kettering Cancer Center, New York, NY

  • Barwon Health, University Hospital Greelong, Greelong, Australia

  • Service des Maladies du Sang, CHU Lille, Lille, France

  • Columbia University Irving Medical Center, New York, NY

  • Levine Cancer Institute, Atrium Health, Charlotte, NC

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Rocky Mountain Cancer Centers, Boulder, CO

Locations

  • United States

  • France

  • United Kingdom

  • Australia

Companies

  • Epizyme, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Follicular lymphoma

  • Thrombocytopenia

  • Neutropenia

  • Lymphomas

Biomarkers

  • Enhancer of zeste homolog 2

  • Tafazzin

Drug/Treatment

  • Lenalidomide

  • Tazemetostat

  • Rituximab

  • EZH2

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Pharmacokinetics

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved